FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029973196> ?p ?o ?g. }

• W2029973196 abstract "Immunological and clinical effects of post-transplant growth factor administration have not been well studied. This report describes the outcome and immune functions of a total of 50 HLA-matched related donor allogeneic blood stem-cell transplantation patients who received post-transplant G-CSF (10 microg/kg) or placebo.Immune status, including number of lymphocyte subsets and their functions, and serum immunoglobulin levels and clinical status--including GvHD, rate of relapse, event-free survival, and overall survival--were determined in the patients enrolled in this study.Twenty-eight patients survived 1 year after transplant, and 15 patients had available results to compare immune function by randomization assignment. At 12 months post-transplant, immune parameters in G-CSF versus placebo groups showed no statistically significant differences in number of circulating lymphocyte subsets CD3, CD4, CD8, CD19 and CD56 in the two groups. There was no significant (NS) difference in immunoglobulin IgG, IgA and IgM levels, NK or LAK cell-mediated cytotoxicity levels, and mitogen-induced proliferation between post-transplant G-CSF and placebo group. In addition, the analyses of immune parameters at earlier time-points on Days 28, 100, 180, and 270 revealed that, except for LAK cytotoxicity at Day 100, there was no differences between the two groups. Fourteen of 26 patients are alive in the G-CSF arm and nine of 24 in the placebo arm. Median follow-up of surviving patients is 43 months. Four year overall and event-free survival in the G-CSF and the placebo group were 53% and 35% (NS), and 44% and 36% (NS) respectively. Bacterial or fungal infections were the cause of six of 12 deaths in the G-CSF arm (all bacterial) and of four of 15 deaths in the placebo arm (two deaths from Aspergillus) (P=0.26). Two patients relapsed in the G-CSF arm and three in the placebo arm. Four year cumulative incidences of relapse were 8% versus 13% in G-CSF versus placebo arms, respectively, (NS). Chronic GvHD developed in 14 of 19 100-day survivors after G-CSF (11 extensive stage), and in 17 of 20 (14 extensive stage) in the placebo arm. The 4-year cumulative incidence of chronic GvHD was 56% [95% confidence interval (CI) 24-88%] after G-CSF and 71% (95% CI 48-94%) after placebo; this difference was not statistically significant (log rank P=0.41).In summary, there were no significant immunological or alterations in clinical benefit of post-transplant G-CSF administration in T-replete allotransplant recipients." @default.
• W2029973196 created "2016-06-24" @default.
• W2029973196 creator A5015628512 @default.
• W2029973196 creator A5017386283 @default.
• W2029973196 creator A5021230880 @default.
• W2029973196 creator A5035051206 @default.
• W2029973196 creator A5037672073 @default.
• W2029973196 creator A5043166717 @default.
• W2029973196 creator A5057320405 @default.
• W2029973196 creator A5058635140 @default.
• W2029973196 creator A5061471602 @default.
• W2029973196 creator A5066299608 @default.
• W2029973196 creator A5067292776 @default.
• W2029973196 creator A5079085880 @default.
• W2029973196 creator A5080373697 @default.
• W2029973196 creator A5084629708 @default.
• W2029973196 creator A5086587597 @default.
• W2029973196 creator A5089893290 @default.
• W2029973196 date "2003-12-01" @default.
• W2029973196 modified "2023-09-27" @default.
• W2029973196 title "Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: Results from a randomized double-blind study" @default.
• W2029973196 cites W1486301687 @default.
• W2029973196 cites W1565467869 @default.
• W2029973196 cites W168192535 @default.
• W2029973196 cites W1842423069 @default.
• W2029973196 cites W1934677454 @default.
• W2029973196 cites W1972663298 @default.
• W2029973196 cites W1987968353 @default.
• W2029973196 cites W2024835620 @default.
• W2029973196 cites W2055945660 @default.
• W2029973196 cites W2088211433 @default.
• W2029973196 cites W2163682534 @default.
• W2029973196 cites W2168048025 @default.
• W2029973196 cites W2247696063 @default.
• W2029973196 cites W2274303087 @default.
• W2029973196 cites W2302959632 @default.
• W2029973196 cites W2317548431 @default.
• W2029973196 cites W2322430525 @default.
• W2029973196 cites W2337680764 @default.
• W2029973196 cites W2419199060 @default.
• W2029973196 cites W2895334128 @default.
• W2029973196 cites W64434556 @default.
• W2029973196 cites W72244411 @default.
• W2029973196 doi "https://doi.org/10.1080/14653240310003648" @default.
• W2029973196 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14660050" @default.
• W2029973196 hasPublicationYear "2003" @default.
• W2029973196 type Work @default.
• W2029973196 sameAs 2029973196 @default.
• W2029973196 citedByCount "5" @default.
• W2029973196 countsByYear W20299731962015 @default.
• W2029973196 crossrefType "journal-article" @default.
• W2029973196 hasAuthorship W2029973196A5015628512 @default.
• W2029973196 hasAuthorship W2029973196A5017386283 @default.
• W2029973196 hasAuthorship W2029973196A5021230880 @default.
• W2029973196 hasAuthorship W2029973196A5035051206 @default.
• W2029973196 hasAuthorship W2029973196A5037672073 @default.
• W2029973196 hasAuthorship W2029973196A5043166717 @default.
• W2029973196 hasAuthorship W2029973196A5057320405 @default.
• W2029973196 hasAuthorship W2029973196A5058635140 @default.
• W2029973196 hasAuthorship W2029973196A5061471602 @default.
• W2029973196 hasAuthorship W2029973196A5066299608 @default.
• W2029973196 hasAuthorship W2029973196A5067292776 @default.
• W2029973196 hasAuthorship W2029973196A5079085880 @default.
• W2029973196 hasAuthorship W2029973196A5080373697 @default.
• W2029973196 hasAuthorship W2029973196A5084629708 @default.
• W2029973196 hasAuthorship W2029973196A5086587597 @default.
• W2029973196 hasAuthorship W2029973196A5089893290 @default.
• W2029973196 hasConcept C126322002 @default.
• W2029973196 hasConcept C142724271 @default.
• W2029973196 hasConcept C167672396 @default.
• W2029973196 hasConcept C203014093 @default.
• W2029973196 hasConcept C204243189 @default.
• W2029973196 hasConcept C204787440 @default.
• W2029973196 hasConcept C27081682 @default.
• W2029973196 hasConcept C2777761686 @default.
• W2029973196 hasConcept C2778957590 @default.
• W2029973196 hasConcept C2911091166 @default.
• W2029973196 hasConcept C535046627 @default.
• W2029973196 hasConcept C71924100 @default.
• W2029973196 hasConcept C8891405 @default.
• W2029973196 hasConcept C90924648 @default.
• W2029973196 hasConceptScore W2029973196C126322002 @default.
• W2029973196 hasConceptScore W2029973196C142724271 @default.
• W2029973196 hasConceptScore W2029973196C167672396 @default.
• W2029973196 hasConceptScore W2029973196C203014093 @default.
• W2029973196 hasConceptScore W2029973196C204243189 @default.
• W2029973196 hasConceptScore W2029973196C204787440 @default.
• W2029973196 hasConceptScore W2029973196C27081682 @default.
• W2029973196 hasConceptScore W2029973196C2777761686 @default.
• W2029973196 hasConceptScore W2029973196C2778957590 @default.
• W2029973196 hasConceptScore W2029973196C2911091166 @default.
• W2029973196 hasConceptScore W2029973196C535046627 @default.
• W2029973196 hasConceptScore W2029973196C71924100 @default.
• W2029973196 hasConceptScore W2029973196C8891405 @default.
• W2029973196 hasConceptScore W2029973196C90924648 @default.
• W2029973196 hasLocation W20299731961 @default.
• W2029973196 hasLocation W20299731962 @default.
• W2029973196 hasOpenAccess W2029973196 @default.
• W2029973196 hasPrimaryLocation W20299731961 @default.
• W2029973196 hasRelatedWork W2001113033 @default.

• next